PMC:7784786 / 3908-4157 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"150","span":{"begin":210,"end":218},"obj":"Species"},{"id":"154","span":{"begin":100,"end":110},"obj":"Chemical"},{"id":"157","span":{"begin":201,"end":209},"obj":"Disease"}],"attributes":[{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"Tax:9606"},{"id":"A154","pred":"tao:has_database_id","subj":"154","obj":"MESH:C000597346"},{"id":"A157","pred":"tao:has_database_id","subj":"157","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"On account of its well proven effect on T-cell activation and proinflammatory cytokines production, itolizumab was included as part of a Cuban expanded access protocol in critical, severe and moderate COVID-19 patients with high risk of aggravation."}

{"project":"LitCovid-sentences","denotations":[{"id":"T35","span":{"begin":0,"end":249},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"On account of its well proven effect on T-cell activation and proinflammatory cytokines production, itolizumab was included as part of a Cuban expanded access protocol in critical, severe and moderate COVID-19 patients with high risk of aggravation."}